Calgary, Alberta--(Newsfile Corp. - June 12, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced a peer-reviewed article, entitled, "Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment," by Dr. Dean Gilham and colleagues, was published in Biomedicines, a prestigious scientific journal. The article explores the favorable impact of apabetalone treatment on kidney cells and its implications for the prevention of negative cardiovascular outcomes in people suffering from chronic kidney disease (CKD).

The article is published online HERE.

Publication Highlights Include:

• Loss of kidney function is an independent risk factor for cardiovascular disease, as cardiovascular events are the leading cause of death in CKD patients.
• In the phase 3 BETonMACE trial, apabetalone reduced risk of major adverse cardiac events (MACE) by an extraordinary 50% among participants with reduced kidney function.
• In this study, activated human kidney cells were treated with apabetalone to investigate its impact on disease associated pathways and processes.
• Apabetalone treatment suppressed the expression of key drivers of fibrosis, inflammation, and calcification, all of which contribute to development and progression of CKD, and negatively impact the kidney-heart axis.
• These findings were confirmed by proteomic analysis of blood samples taken from CKD patients treated with apabetalone.

"We saw, in BETonMACE, that apabetalone treatment improved cardiovascular outcomes in patients with reduced kidney function." said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. "This study provides insight into the underlying mechanisms that contribute to this positive outcome."

Additionally, Resverlogix announced today its participation in the upcoming scientific conference hosted by the European Renal Association in Milan, Italy. A poster, entitled "Apabetalone Reduces Cardiac Events in CKD Patients by Downregulating Fibrotic and Inflammatory Processes", will be presented by BETonMACE Clinical Steering Committee member and UCLA nephrologist, Dr. Kam Kalantar-Zadeh on Friday June 16th, 2023, at 8:30 AM (CET).

Koo